Last reviewed · How we verify
Wilate
At a glance
| Generic name | Wilate |
|---|---|
| Also known as | von Willebrand factor / Factor VIII (plasma derived) |
| Sponsor | Emory University |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age (PHASE3)
- Von Willebrand Factor in Pregnancy (VIP) Study
- Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients
- Treatment of Hemophilia A Patients With FVIII Inhibitors
- A Pilot Crossover Trial of Prophylactic Wilate Compared to Placebo for Heavy Menstrual Bleeding in Patients with VWD (PHASE3)
- Enhancement of the Haemostatic Effect of Platelets in the Presence of High Normal Concentrations of Von Willebrand Factor (PHASE4)
- Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq
- Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Wilate CI brief — competitive landscape report
- Wilate updates RSS · CI watch RSS
- Emory University portfolio CI